| CAS NO: | 106133-20-4 |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 106133-20-4 |
| 别名 | 坦索罗辛; (R)-(-)-YM12617 free base; LY253351 free base |
| Canonical SMILES | O=S(C1=CC(C[C@H](NCCOC2=CC=CC=C2OCC)C)=CC=C1OC)(N)=O |
| 分子式 | C20H28N2O5S |
| 分子量 | 408.51 |
| 溶解度 | DMSO: 100 mg/mL (244.79 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Tamsulosin is a selective α1 receptor antagonist.Target: α1 receptorTamsulosin is a selective α1 receptor antagonist that has preferential selectivity for the α1A receptor in the prostate versus the α1B receptor in the blood vessels. Tamsulosin-treated patients had a 0.30-fold lower risk of developing acute urinary retention compared with control patients. None of the International Continence Society male questionnaire domain scores showed significant changes between the groups [1]. tamsulosin can be recommended for treating men after catheterization for AUR, and can reduce the likelihood of the need for re-catheterization [2]. [1]. Jeong, I.G., et al., Impact of tamsulosin on urinary retention following early catheter removal after robot-assisted laparoscopic radical prostatectomy: a prospective randomized controlled trial. Int J Urol, 2014. 21(2): p. 164-8. [2]. Lucas, M.G., T.P. Stephenson, and V. Nargund, Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int, 2005. 95(3): p. 354-7. |
m.cnreagent.com